REFERENCES
- Collier AC, Coombs RW, Schoenfeld DA, et al. for the AIDS Clinical Trials Group. Treatment of human immunodefi-ciency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med.1996;334:1011-1017.
- Merry C, Barry MG, Mulcahy F, Halifax KL, Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS. 1997;11:F117—F120.
- Jensen-Fangel S, Kirk O, Larsen L, et al. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected pa-tients naive to antiretroviral therapy: A retrospective cohort study. Scand J Infect Dis. 1999;31:489–493.
- Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113—F116.
- Monforte AD, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS. 1998;12:1631–1637.
- Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients start-ing highly active antiretroviral therapy in Europe. Arch In-tern Med. 2000;160:1123–1132.
- Grabar S, Pradier C, Corfec EL, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000;14:141–149.
- Para MF, Glidden DV, Coombs RW, et al. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-cap-sule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS Clinical Trials Group Protocol 333. J Infect Dis. 2000;182:733–743.
- Lawrence J, Schapiro J, Winters M, et al. Clinical resis-tance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. J Infect Dis. 1999;179: 1356–1364.
- Craig C, Race E, Sheldon J, et al. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS. 1998;12:1611–1618.
- Kirk O, Katzenstein T, Gerstoft J, et al. Combination therapy containing ritonavir plus saquinavir has superior short term antiretroviral efficacy: A randomised trial. AIDS. 1999;13:F9—F16.
- The AVANTI Steering Committee. Analysis of HIV-1 clinical trials: Statistical magic? Lancet. 1999;353:2061–2064.
- Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-1 infected indi-viduals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723–724.
- Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS. 1999;13:F35—F43.
- Schapiro JD, Winters MA, Lawrence J, Merigan TC. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS. 1999;13:359–365.
- Mitsuyasu RT, Skolnik PR, Cohen SR, et al. on behalf of the NV15355 Study Team. Activity of the soft gelatine formula-tion of saquinavir in combination therapy in antiretroviral-naive patients. AIDS. 1998;12:F103—F109.
- Stuart JWTC, Schuurman R, Burger DM, et al. Randomized trial comparing saquinavir gelatine capsules versus indinavir as part of triple therapy (CHEESE study). AIDS. 1999;13:F53—F58.